KRAS and metastatic neoplasm: In line with these observations, we detected enrichment of KRAS/BRAF mutations and increased KRAS signaling activity in primary stage II tumors (AMC-AJCCII-90) that will eventually recur as peritoneal metastatic disease (Supplementary Fig. 2a, b).